High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease

Area of Science:

• Immunology
• Gastroenterology
• Hematology

Background:

• Severe Crohn disease (CDAI > 250) poses significant challenges, especially when refractory to anti-tumor necrosis factor alpha (TNF-alpha) therapies.
• Current treatment paradigms for severe, refractory Crohn disease are limited, necessitating exploration of novel therapeutic strategies.

Observation:

• Two patients with severe Crohn disease, previously unresponsive to anti-TNF-alpha treatment, underwent autologous hematopoietic stem cell transplantation (HSCT).
• The HSCT protocol involved stem cell mobilization with cyclophosphamide and G-CSF, CD34+ selection, and immune conditioning with cyclophosphamide and anti-thymocyte globulin (ATG).

Findings:

• Both patients achieved and maintained clinical remission (CDAI < 100) for at least one year post-HSCT.
• The intensive immunosuppression and autologous HSCT regimen demonstrated significant efficacy in managing severe Crohn disease.

Implications:

• Autologous HSCT represents a viable and potentially curative therapeutic option for select patients with severe, refractory Crohn disease.
• Further clinical studies investigating HSCT for severe Crohn disease are warranted to establish its broader efficacy and safety profile.